Compounds > emtricitabine--tenofovir-disoproxil-fumarate-drug-combination

emtricitabine--tenofovir-disoproxil-fumarate-drug-combination and Drug-Hypersensitivity

emtricitabine--tenofovir-disoproxil-fumarate-drug-combination has been researched along with Drug-Hypersensitivity* in 2 studies

Other Studies

2 other study(ies) available for emtricitabine--tenofovir-disoproxil-fumarate-drug-combination and Drug-Hypersensitivity

ArticleYear
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Adolescent; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Drug Hypersensitivity; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Male; Organophosphorus Compounds

2007
Two-once-daily fixed-dose NRTI combinations for HIV.
    The Medical letter on drugs and therapeutics, 2005, Feb-28, Volume: 47, Issue:1203

    Abacavir/lamivudine (Epzicom) and emtricitabine/tenofovir (Truvada), two new once-daily fixed-dose NRTI combinations, have been approved for use in antiretroviral regimens to treat HIV infection. Epzicom appears to be as effective as its components taken separately and, in one study, Truvada was at least as effective as zidovudine/lamivudine (Combivir). Use of once-daily fixed-dose combinations means less flexibility in dosing, and some patients with hepatic or renal impairment will not be able to take them.

    Topics: Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Hypersensitivity; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Lamivudine; Organophosphorus Compounds

2005